U.S. Pistent and Trademark Office, U.S. City, U.S. City

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)
(Not for Submission ander or or it now)

Application Number		
Filing Date		2006-06-06
First Named Inventor Shell		a Herman
Art Unit		
Examiner Name		
Attorney Docket Number		35627-103386

		Remove				
Examiner Cite No Patent		Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5215309		1993-06-01	JOEL	
		6428004		2002-08-06	MCQUITTY	
		6322076		2001-11-27	FIKKI	
	4	5931469		1999-08-03	STICHNOTH	
	5	5556100		1996-09-17	TAYLOR ET AL.	
	6	5350179		1994-09-27	HILL	
	7	6669196		2003-12-30	WASHKO	
	8	6279908		2001-08-28	HUNSBERGER	

INFORMATION DISCLOSURE First Named Inventor Sheila Herman STATEMENT BY APPLICANT Art I Init ( Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 35627-103386 5704611 1008.01.06 PIFRCE 10 4440396 1984-04-03 FRUDAKIS 11 4136879 1979-01-30 ANDREW ET AL Add If you wish to add additional U.S. Patent citation information please click the Add button. Remove HIS PATENT APPLICATION PHRI ICATIONS Pages, Columns, Lines where Kind Publication Name of Patentee or Applicant Examiner Cite Publication Number Relevant Passages or Relevant Initial\* No Code<sup>1</sup> Date of cited Document Figures Appear If you wish to add additional U.S. Published Application citation information please click the Add button. Add FOREIGN PATENT DOCUMENTS Pages, Columns, Lines Name of Patentee or Kind Publication where Relevant Examiner Cite Foreign Document Country Applicant of cited Initial\* Nο Number<sup>3</sup> Code<sup>2</sup> i Code4 Date Passages or Relevant Document Figures Appear If you wish to add additional Foreign Patent Document citation information please click the Add button Add NON-PATENT LITERATURE DOCUMENTS Remove Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), T5 Initials\* No publisher, city and/or country where published. International Search Report of International Application PCT/US2004/041564 filed on 9 December 2004

Application Number Filing Date

2006-06-06

	Application Number			
INFORMATION DIGGS COURT	Filing Date		2006-06-06	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Sheila	la Herman	
( Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Number		35627-103386	

If you wish to add additional non-patent literature document citation information please click the Add button Add					
	EXAMINER SIGNATURE				
Examiner Signature		Date Considered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kint Code of USPTO Patent Documents at invent USPTO\_GDV or MPEP 80104. 2 Enter office that issued the document, by the involved or KIPCO Standard ST3.) 3 For Laplanese patent document, the critical most on the year of the region of the Emporer many precise the sent annumber of the patent document. If Annumber of the Counter of the

#### 

### CERTIFICATION STATEMENT

Diagra can	37	CER 4	97	and	1 98 to	make the	annronniato	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/jrc/	Date (YYYY-MM-DD)	2006-06-06						
Name/Print	Jagrit Chander	Registration Number	46610						

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.